Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices

ConclusionsThe results showed that patients who received ramucirumab monotherapy started ramucirumab therapy later after diagnosis and were older than those who received ramucirumab in combination. Additionally, survival data suggest that outcomes observed in community oncology practices are similar to data from phase 3 clinical trials.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research